Search
Mineralys Therapeutics Inc
MLYSAdd to Watchlist
26.890USD
-0.090-0.33%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.37BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
10
analysts
Buy
Current Rating
49.000
Target Price
+81.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Mineralys Therapeutics Inc
MLYS
10
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Mineralys Therapeutics Inc's price target?
Analysts forecast that Mineralys Therapeutics Inc's price target is USD 44.50, with the highest forecast at USD 52.00 and the lowest forecast at USD 26.00.
How have Mineralys Therapeutics IncMLYS's recent earnings per share performed?
The market expectation was USD -0.47, while Mineralys Therapeutics IncMLYS's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.53.
What is the analyst rating for Mineralys Therapeutics Inc?
Based on the ratings of Mineralys Therapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.